Prostate Cancer
Addressing Health Disparities in the Care of Advanced Prostate Cancer: An Expert Panel Discussion
This activity is supported by independent educational grants from Astellas Pharma Global Development, Inc.; Lantheus; Merck Sharp & Dohme LLC; and Pfizer Inc.
AI model identifies tumor volume as risk factor for prostate cancer metastasis, recurrence
An AI model revealed tumor size to be an independent factor when determining risk for prostate cancer recurrence or metastasis, according to results of a retrospective study.
Q&A: Prostate cancer screening misconceptions common but combatable
Primary care providers should discuss prostate cancer screening with eligible patients and work to dispel common misconceptions that keep men from getting screened, according to an expert.
Healthy diet ‘a concrete step’ to reduce risk for prostate cancer progression
Greater adherence to American dietary guideline recommendations appeared linked with reduced likelihood of prostate cancer progression among men undergoing active surveillance, study results showed.
Cancer detection rates improved the second year of the pandemic, but deficits remained
Cancer diagnoses fell significantly below expectations in 2020 due to the COVID-19 pandemic but recovered to projected levels the following year, according to results of a cross-sectional study.
Omega-3, omega-6 fatty acids may protect against several cancers
Higher omega-3 and omega-6 fatty acid levels may help reduce cancer risk, according to study findings.
High-dose androgens may ‘rewrite the textbooks’ on prostate cancer treatment
One journal reviewer told Donald P. McDonnell, PhD, the research should be “banned from the literature.”
Pesticides linked to prostate cancer incidence, mortality
Certain pesticides may increase the risk for prostate cancer incidence and mortality, according to results of an environment-wide association study.
Transperineal prostate biopsies reduce infection, should be a ‘gold standard’
A transperineal approach to prostate cancer biopsies without the need for preventive antibiotics could eliminate risk for infection, according to results of a randomized trial.
Enzalutamide confers small benefit vs. abiraterone in metastatic prostate cancer
Enzalutamide conferred small but statistically significant improvements in outcomes vs. abiraterone acetate for men with metastatic castration-resistant prostate cancer, according to retrospective study results.